Recent Advances in Oral Peptide or Protein-Based Drug Liposomes

The high physiology and low toxicity of therapeutic peptides and proteins have made them a hot spot for drug development in recent years. However, their poor oral bioavailability and unstable metabolism make their clinical application difficult. The bilayer membrane of liposomes provides protection...

Full description

Saved in:
Bibliographic Details
Published inPharmaceuticals (Basel, Switzerland) Vol. 15; no. 9; p. 1072
Main Authors Cui, Jian, Wen, Zhiwei, Zhang, Wei, Wu, Wei
Format Journal Article
LanguageEnglish
Published Basel MDPI AG 28.08.2022
MDPI
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:The high physiology and low toxicity of therapeutic peptides and proteins have made them a hot spot for drug development in recent years. However, their poor oral bioavailability and unstable metabolism make their clinical application difficult. The bilayer membrane of liposomes provides protection for the drug within the compartment, and their high biocompatibility makes the drug more easily absorbed by the body. However, phospholipids—which form the membranes—are subjected to various digestive enzymes and mucosal adhesion in the digestive tract and disintegrate before absorption. Improvements in the composition of liposomes or modifying their surface can enhance the stability of the liposomes in the gastrointestinal tract. This article reviews the basic strategies for liposome preparation and surface modification that promote the oral administration of therapeutic polypeptides.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
These authors contributed equally to this work.
ISSN:1424-8247
1424-8247
DOI:10.3390/ph15091072